Hair loss drug showdown: which works better?
NCT ID NCT07190534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two medicines, hydroxychloroquine and methotrexate, to see which works better for frontal fibrosing alopecia, a type of scarring hair loss that mainly affects women. About 50 adults who choose to start one of these treatments will be followed for up to 48 weeks. The goal is to measure how well each medicine controls disease activity and improves quality of life, helping doctors make better treatment recommendations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erasmus MC University Medical Center
Rotterdam, South Holland, 3015GD, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug aims to halt scarring hair loss
- Can a cream regrow hair lost to frontal fibrosing alopecia?
- New drug shows promise for irreversible hair loss
- New pill could stop scarring hair loss in its tracks
- Could a new drug halt hair loss from frontal fibrosing alopecia?
- New laser zaps annoying facial bumps in hair loss condition